Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

Summary

This study is intended to evaluate the potential to relieve the symptoms associated with gastroparesis during 12 weeks of treatment with oral tablets given twice a day of GM-611 5mg, 10mg or placebo to type I or II diabetics who require insulin. Additionally the study will evaluate the safety and tolerability of GM-611 compared to placebo, the levels of GM-611 in the blood, and the possible effect of GM-611 on diabetic control.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications